Close Menu

NEW YORK (GenomeWeb) – Inivata said today that Medicare administrative contractor Palmetto GBA has finalized its draft local coverage determination (LCD) for the company's liquid biopsy lung cancer test, InVisionFirst-Lung.

The policy, which becomes effective April 8, provides specific coverage for the test for all fee-for-service Medicare patients in the US with advanced (Stage IIIB/IV) NSCLC who meet specific clinical criteria.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

New US Department of Commerce rules will affect supercomputing in China, according to the Wall Street Journal.

A new analysis finds that it will be more than a century until female computer scientists publish at the same rate as their male counterparts, ScienceInsider reports.

Broad Institute researchers describe an approach they've dubbed "DNA microscopy."

In PLOS this week: epigenetic changes following hepatitis C virus treatment, metagenomic analysis of Ugandan children with febrile illness, and more.